M. Schupp

Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study

R. Plummer, U. Vaishampayan, Y. Ou, 2017, Experimental Hematology & Oncology.

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

M. Kersten, P. Riedell, L. Gordon, 2021, The New England journal of medicine.

A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors

E. Van Cutsem, Yoon-Koo Kang, D. Cunningham, 2018, Clinical Cancer Research.

A Randomized, Placebo‐Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum‐Based Chemotherapy as First‐Line Treatment for Extensive‐Stage Small‐Cell Lung Cancer

K. Nackaerts, R. Ramlau, L. Paz-Ares, 2017, Clinical lung cancer.

A new case of Carney triad: gastrointestinal stromal tumours and leiomyoma of the oesophagus do not show activating mutations of KIT and platelet-derived growth factor receptor α

H. Einsele, E. Wardelmann, L. Kanz, 2006, Journal of Clinical Pathology.

Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

M. Kersten, P. Riedell, L. Gordon, 2021, Blood.

Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation—a phase II study

C. Bokemeyer, L. Kanz, F. Mayer, 2002, Anti-cancer drugs.

Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.

G. Batist, T. Shore, F. Porzsolt, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

M. Kersten, P. Riedell, L. Gordon, 2021, New England Journal of Medicine.

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.

M. Kersten, P. Riedell, D. Miklos, 2023, The New England journal of medicine.

Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)

S. de Vos, L. Lekakis, J. Westin, 2023, Blood cancer discovery.